Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.

Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.

Publication date: Mar 12, 2019

No postmarketing randomised clinical trials are available about alemtuzumab, and real-world data are limited. We aimed to analyse the efficacy and safety of alemtuzumab in a single-centre cohort of patients with relapsing-remitting MS.

Patients who took alemtuzumab were enrolled. We collected the following data: age, sex, MS history, expanded disability status scale (EDSS), relapses, magnetic resonance imaging (MRI) parameters after alemtuzumab, and adverse events. EDSS scores before alemtuzumab and at the last follow-up were compared by Wilcoxon test. Time to first relapse was analysed after dividing the cohort on the basis of previous treatment.

Ninety patients were enrolled [women 74.4%; nacEFve 7; mean follow-up 27 months (SD 23)]. The EDSS was reduced from a median of 2.5 (IQR 1.5-4) before alemtuzumab to 2.0 (IQR 1.5-3.5) after (p = 0.025). The time to first relapse was shorter in patients shifting from a second-line therapy (p = 0.011). Over 2 years, 43.7% had no evidence of disease activity. We observed infusion-related reactions in 95.5% patients, including 11.1% with pneumonitis, thyroiditis in 11%, and thrombocytopenia in 3.3%.

We confirmed the clinical and MRI efficacy of alemtuzumab in the clinical setting and the frequency of infusion-related reactions. Compared with that in clinical trials, higher number of patients developed pneumonitis during infusion.

Frau, J., Coghe, G., Lorefice, L., Fenu, G., Musu, L., and Cocco, E. Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis. 17503. 2019 J Neurol.

Concepts Keywords
Alemtuzumab Magnetic resonance imaging
Clinical Trials MRI
Cohort Monoclonal antibody
Disability Multiple sclerosis
Frequency Immune system
Infusion Immunology
IQR Biology
Magnetic Resonance Imaging Alemtuzumab
MRI Sanofi
Multiple Sclerosis Medicine
Nave Medical specialties
Pneumonitis MS
Relapse Pneumonitis thyroiditis
Thrombocytopenia Thrombocytopenia
Thyroiditis Pneumonitis

Semantics

Type Source Name
disease DOID thrombocytopenia
disease MESH thrombocytopenia
disease DOID thyroiditis
disease MESH thyroiditis
disease MESH pneumonitis
gene UNIPROT CYREN
disease MESH relapses
disease DOID relapsing-remitting MS
disease DOID multiple sclerosis
disease MESH multiple sclerosis
drug DRUGBANK Alemtuzumab

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *